Halper Sadeh LLC is investigating whether shareholders of Nuvalent, SUNation Energy, Organon & Co., and Taylor Morrison Home Corporation are receiving fair treatment in their companies' recent sales or mergers. The law firm highlights potential conflicts where insiders may gain benefits not available to ordinary shareholders and notes that deal terms might limit better competing offers. Shareholders are encouraged to contact Halper Sadeh LLC to explore their rights and possibly seek increased compensation or other remedies. This investigation could impact the final terms and shareholder returns in these transactions.
GSK has agreed to acquire Boston-based biotech firm Nuvalent for $10.6 billion in cash, paying $124 per share, a 40% premium over the last closing price. This marks GSK's largest acquisition in over a decade and aims to strengthen its lung cancer dru...
Monteverde & Associates PC is investigating the sale of Nuvalent, Inc. to GSK plc, where Nuvalent shareholders are set to receive $124 per share in cash. The investigation questions whether this deal is fair to shareholders. The law firm, known for r...
British pharmaceutical company GSK announced it will acquire cancer drug developer Nuvalent for $10.6 billion. This deal caused Nuvalent's stock to surge 39% as investors reacted positively to the acquisition. The move highlights GSK's strategic inve...
GSK has agreed to acquire US biotech firm Nuvalent for $10.6 billion (£8 billion) to enhance its oncology portfolio with advanced lung cancer treatments and other assets. The deal includes late-stage drugs zidesamtinib and neladalkib, both under FDA ...
UK pharmaceutical company GSK is negotiating to acquire oncology biotech Nuvalent for more than $9 billion, potentially finalizing the deal this week. This acquisition would be GSK's largest in over ten years and marks a shift from its recent smaller...
